Temsirolimus 25mg (Temsirolimus)

Description of Torisel 25mg (Temsirolimus 25mg)

Torisel 25mg (Temsirolimus 25mg) is a derivative of rapamycin, an agent that exhibits antifungal, immunosuppressant and antitumor activities.

Torisel 25mg (Temsirolimus 25mg) is a targeted therapy medicines required to treat kidney cancer which has spread, and mantle cell lymphoma that has come back after treatmentand be indicated to treat other cancers.

Torisel 25mg (Temsirolimus 25mg) is a prescription medicines which is used under the supervision of medical oncologist.

Medical use /Indication of Torisel 25mg (Temsirolimus 25mg)

Torisel 25mg (Temsirolimus 25mg) is a derivative of rapamycin, an agent that exhibits antifungal, immunosuppressant and antitumor activities.

Torisel 25mg (Temsirolimus 25mg) is a targeted therapy medicine required to treat kidney cancer which has spread, and mantle cell lymphoma that ha ome back after treatmentand be indicated to treat other cancers.

Torisel 25mg (Temsirolimus 25mg) is a prescription medicines which is used under the supervision of medical oncologist.

Mechanism of Action Torisel 25mg (Temsirolimus 25mg)

Temsirolimus is a rapamycin derivative, an agent which exhibits antifungal, immunosuppressant and antitumor activities.

Temsirolimus appears to inhibit the effects of mTOR, an enzyme which has an important role in controlling the synthesis of proteins that regulates cell division.

Therefore, Temsirolimus may discontinue the production of proteins necessary for cancer cell replication.

Absorption of Torisel 25mg (Temsirolimus 25mg)

Time to peak plasma time is 0.5-2 hr after infusion (sirolimus)

Distribution of Torisel 25mg (Temsirolimus 25mg)

The Torisel 25mg (Temsirolimus 25mg) has volumeof distribution is 172 L

Metabolism of Torisel 25mg (Temsirolimus 25mg)

Torisel 25mg (Temsirolimus 25mg) is Metabolized in liver; through CYP3A4 to active metabolite sirolimus and several other metabolites

Excretion of Torisel 25mg (Temsirolimus 25mg)

The medicine Torisel 25mg (Temsirolimus 25mg) excreted through feces 78% and urine <5%

Half-Life: 17hr (Temsirolimus); 55hr (sirolimus)

Side effects of Torisel 25mg (Temsirolimus 25mg)

More common side effects :

Hypophosphatemia, Weakness, Low blood counts , Rash, Mouth sores , Increased liver enzymes, Nausea, Swelling , Poor appetite , Hyperglycaemia, High in blood cholesterol levels , Increased blood creatine levels.

Less common side effects for patients receiving Temsirolimus :

Weight loss , Chest pain , Headache , nail disorder/thinning , Insomnia , Nose bleed , Sore throat, Dry skin, Reduce white blood cell count, Generalized aches and pains , Shortness of breath , Pain, Swelling in legs and feet , Diarrhea , Cough , Fever , Low potassium , Abdominal pain, Infection, Constipation , Taste disturbance , Back pain , Itching, Vomiting .

Precautions of Torisel 25mg (Temsirolimus 25mg)

• While treatment it may have high risks of hypersensitivity reactions; hyperglycaemia; hyperlipidemia; intracerebral hemorrhage (CNS tumor and/or on anticoagulants)
• Infections may report from immunosuppression
• Renal failure, sometimes fatal, has resulted; monitor renal function at baseline and while on therapy
• Due to atypical wound healing, use caution in perioperative period
• Bowel perforation may result; monitor fever, abdominal pain, bloody stools, and/or acute abdomen immediately
• Elderly patients may be more likely to experience certain adverse reactions, containing diarrhea, edema and pneumonia
• Pregnancy should be avoided during and for 3 months post-treatment

Drug interaction of Torisel 25mg (Temsirolimus 25mg)

• When Torisel 25mg (Temsirolimus 25mg)concomitant use with rifampin, a potent CY3A4/5 had no significant effect on Temsirolimus but reduced sirolimus Cmax by 65%.
• Interaction of Torisel 25mg (Temsirolimus 25mg)with ketoconazole, a potent CY3A4 inhibitor had no significant effect on Temsirolimus but have high sirolimus Cmax by 65%.
• Co administration of Torisel 25mg (Temsirolimus 25mg) with ramipril and/or amlodipine, angioedema has been resulted in patients taking mammalian target of rapamycin

Pregnancy of Torisel 25mg (Temsirolimus 25mg)

Pregnancy category is D

Avoid using Torisel 25mg (Temsirolimus 25mg) during pregnancy for during or post-treatment until 3 months

Lactation of Torisel 25mg (Temsirolimus 25mg)

The mediciens excreted into human milk is unknown and effects in the new born baby are unknown
Hence use is contraindicated
Avoid breastfeed during the treatment with Torisel 25mg (Temsirolimus 25mg)

Dosage of Torisel 25mg (Temsirolimus 25mg)

Advanced Renal cell carcinoma :

The patients should be Pre-treat with antihistamines (e.g. diphenhydramine 25-50 mg IV 30 minutes preinfusion

The Torisel 25mg (Temsirolimus 25mg) recommended dose is 25mg IV infusion qweek until disease progression or unacceptable
Stop if ANC <1000/mm³ and/or platelets <75000/mm³ and/or Grade 3 or higher AE; again, proceed after toxicity is decreased to at least Grade 2 at 5 mg lower dose but no lower than 15 mg.

Storage of Torisel 25mg (Temsirolimus 25mg)

Store at 2℃ to 8℃

Protect from light.

Missed dose of Torisel 25mg (Temsirolimus 25mg)

If dose is missed, then have immediately before the reaching of next dose time or swap the missed dose and continue regular schedule.
Consult the doctors for more information.